BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) — Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for…Read More
Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
